WAIKOLOA, Hawaii — In this expert perspective from Retina 2026, Ehsan Rahimy, MD, a retina specialist at Palo Alto Medical Foundation, discussed promising advancements in the treatment of retinal diseases.
Rahimy said there was a plethora of real-world data published in 2025 on switching patients who had an incomplete or suboptimal response to certain anti-VEGF therapies to “more durable” next-generation therapies, such as Eylea HD (aflibercept 8 mg, Regeneron).
“I’ve been encouraged to see that patients on average have been able to extend treatment intervals out to about 2 to 3 weeks